FRFatemeh Naseri Rad

Fatemeh Naseri Rad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatemeh Naseri Rad has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic accuracy of droplet digital PCR for BRAF mutation detection in thyroid specimens: a systematic review and meta-analysis

    by Danyal Yarahmadi, Ali Maleki Aram, Fatemeh Naseri Rad, Mohammadsadra Shamohammadi, Fatemeh Fayaz Sarcheshmeh, Mohammad Yarahmadi, Ali Yarahmadi

  • Open Access

    Inflammatory and immune-nutritional indices as prognostic markers of mortality after cardiac procedures: evidence from MIMIC-IV

    by Danyal Yarahmadi, Fatemeh Naseri Rad, Mohammad Baadkoube Hazaveh, Yasaman Vaseghi, Ali Rafatnia, Abbas Mohammadi, Carmel Moazez, Babak Goodarzy, Mohammad Mahdi Kakoienejad, Samira Eslami


  • Type 2 diabetes and the increased risk of dementia

    by Ehsan Noroozi, Zeinab Kolahdouzan, Sayedeh-Fatemeh Sadat-Madani, Fatemeh Naseri Rad, Amir Abdi, Alaleh Alizadeh

  • Contributors

    by Hana Abbasian, Amir Abdi, Fatemeh Abediankenari, Rajeswari Aghoram, Lamiaa A. Ahmed, Kenni Wojujutari Ajele, Khaled F. Al-Massri, Alaleh Alizadeh, Shanvanth Arnipalli, Aryadi Arsyad, et al.

  • Open Access

    Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD ): A Systematic Review and Meta‐Analysis

    by Mehdi Karimi, Ali Tahmasebi, Sepehr Ramezanipour, Fatemeh Naseri Rad, Fereshteh Valizadeh, Pegah Abedi, Meisam Gholami, Narges Sobhan Ardekani, Manijeh Ebrahimzadeh Pirshahid

    Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasingly prevalent and associated with obesity and dyslipidemia, yet effective pharmacological interventions remain limited. Empagliflozin has shown potential benefits in MASLD, although evidence remains limited. This systematic review and meta‐analysis assesses the efficacy of empagliflozin in patients with MASLD, both diabetic and non‐diabetic. Methods: An advanced database search was conducted up to June 1st, 2026, to identify eligible randomized controlled trials (RCTs). The relevant data were extracted from selected studies. Pooled effect sizes were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using a random‐effects model. Results: Seven RCTs comprising 591 participants were included. Empagliflozin significantly improved liver enzyme profiles. Specifically, it reduced alanine aminotransferase (ALT) (WMD: −12.24 IU/L; p = 0.037), aspartate aminotransferase (AST) (WMD: −9.51 IU/L; p = 0.048), and gamma‐glutamyl transferase (GGT) (WMD: −14.92 IU/L; p = 0.023). Reductions in alkaline phosphatase (ALP) were observed but did not reach statistical significance (WMD: −26.28 IU/L; p = 0.292). Although substantial heterogeneity was observed for several liver enzyme outcomes. Empagliflozin had no significant effect on lipid parameters, including triglycerides (TG), total cholesterol (TC), low‐density and high‐density lipoprotein cholesterols (LDL‐C, HDL‐C). Empagliflozin also produced a statistically significant but modest reduction in body mass index (BMI) (WMD: −0.71 kg/m 2 ; p < 0.001). Empagliflozin also produced a statistically significant but clinically modest reduction in BMI (WMD: −0.71 kg/m 2 ; 95% CI: −1.00 to −0.43; p < 0.001). Conclusion: Empagliflozin appears to improve liver enzymes and modestly reduce BMI in patients with MASLD, while having a neutral effect on lipid parameters. These findings may confer a statistically significant but clinically modest benefit, particularly in patients with coexisting metabolic risk factors. However, the evidence is limited by small sample sizes, short follow‐up periods, and potential publication bias; therefore, the conclusions should be considered preliminary and hypothesis‐generating.

  • Open Access

    Safety and efficacy of chest tube clamping versus non-clamping prior to removal: a systematic review and meta-analysis

    by Mehdi Kazemloo, Fatemeh Naseri Rad, Leila Goudarzimehr, Mohammadsadra Shamohammadi, Omid Bahrami, Ali Heidari, Matin Emami, Mohammad Baadkoube Hazaveh, Danyal Yarahmadi

    Managing chest tubes before removal remains a controversial clinical issue. Clamping a chest tube before removal is a common practice and is often used to assess latent air leaks. We systematically searched MEDLINE/PubMed, Embase, Scopus, and Web of Science from inception to 11 February 2026 for studies comparing clamping versus no clamping before chest-tube removal. Two reviewers independently screened and extracted data. Random effect meta-analyses used REML with Hartung-Knapp adjustment, pooling risk ratios for pneumothorax and re-intervention, and mean differences (days) for hospital length of stay. The results of this study show no significant differences between the clamping vs. no-clamping in terms of pneumothorax/hemothorax recurrence, re-intervention rates, or hospital length of stay. Within different causes of applying chest tube/ chest drain, routine clamping before chest-tube removal did not reduce early recurrence or the need for re-intervention.

  • Open Access

    The predictive value of lymph node status pre-operation by ultrasound and MRI in early and newly diagnosed breast cancer

    by Hayder Jasim Taher, Roza Baharishargh, Fatemeh Sharifian, Fatemeh Naseri Rad, Sarasadat Mirhosseini, Sanaz Sharifpour, Danyal Yarahmadi, Zeinab Alizadeh

    Background Accurate pre-operative assessment of axillary lymph node status is key for planning surgeries in early and newly diagnosed breast cancer. Ultrasound (US) and magnetic resonance imaging (MRI) are widely used, but their performance is inconsistent across studies. This meta-analysis evaluates and compares the predictive performance of MRI and US for pre-operative lymph node metastasis in early and newly diagnosed breast cancer. Methods We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science (inception-31 December 2025) for studies on diagnostic performance in preoperative axillary staging using ultrasound and/or MRI. Two independent reviewers extracted or reconstructed true positive, true negative, false positive, false negative, and applied QUADAS-2. Sensitivity and specificity were pooled with random-effects GLMM, with direct comparisons and prevalence-based predictive values. Results Twenty-nine studies (n = 8,544) were included. Pooled sensitivity/specificity were 61.1%/92.0% for MRI and 59.8%/90.3% for ultrasound, yielding LR + 7.64 vs. 6.19 and DOR 18.1 vs. 13.9. HSROC AUCs were 0.863 (MRI) and 0.843 (ultrasound). In paired cohorts (k = 12), sensitivity did not differ, and MRI showed a non-significant specificity advantage. Conclusion MRI and ultrasound showed comparable, moderate sensitivity and high specificity for preoperative axillary metastasis. MRI tended toward higher specificity and positive predictive value, whereas sensitivity did not differ in paired studies. Imaging can guide triage, but histopathology remains necessary for definitive staging.

  • Open Access

    Comparison of the effects of inhalant furosemide, oxygen therapy, and placebo in patients with acute dyspnea referred to emergency departments by EMS in various hospitals in Tehran

    by Mahdi Rezai, Danyal Yarahmadi, Mojde Mirkheshti, Mehrad Aghili, Reza Mosadegh, Kourosh Javdani Esfehani, Saeed Abbasi, Fatemeh Naseri Rad

    Acute dyspnea is a common presentation in emergency departments (EDs), which is one of the main complaints of the patients. There is an urgent need for an effective treatment plan for dyspnea. This study aims to compare the efficacy of inhalant furosemide, oxygen therapy, and placebo in patients with acute dyspnea referred to EDs in Tehran by Emergency Medical Services (EMS). This randomized clinical trial included patients aged 18 to 75 who experienced acute dyspnea and were delivered to the ED by EMS during 2021 and 2022. Participants were randomly assigned to one of three groups: inhalant furosemide, oxygen therapy, or placebo (distilled water) which every group received the medication before entering EDs in a prehospital setting. The mean age of patients was 52.63 ± 20.48 years including 124 women (47.7%) and 136 men (52.3%). Our finding indicates that dyspnea intensity, heart rate, blood pressure, and oxygen saturation showed no significant differences among the groups (p-value). However, these parameters significantly improved in both the treatment and placebo groups (p-value). The mean degree of dyspnea in the furosemide group was lower than that in the other two groups, although the difference was not statistically significant. Hospitalization duration was significantly shorter in the furosemide group compared to the oxygen therapy and placebo groups. Conversely, ICU admission duration was significantly shorter in the oxygen therapy group than in the other two groups. Patient satisfaction levels did not differ significantly across groups. The main effect of inhalant Furosemide in this study was reducing the patient’s length of hospitalization. It seems that Furosemide can have positive effects and can be used as a cure according to its low side effects, also this drug isn’t expensive and its mechanism of action, side effects, and pharmacokinetics have been shown and understood. This study was registered with the IUMS Ethics Committee, receiving the ethical code (IR.IUMS.REC.1399.632), it was also listed in the Iranian Registry of Clinical Trails (IRCT20151003024317N12) on November the 10th, 2020.